GenKyoTex
Leader in NOX therapies, based on the selective inhibition of NOX enzymes.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD48m (Public information from Aug 2020)
Company register number 439489022
Archamps France (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 4.6m | 4.7m | 4.3m | 4.4m |
| % growth | - | 1 % | (8 %) | 4 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.6m | Early VC | |
| N/A | $3.8m | Early VC | |
| N/A | CHF2.0m | Series A | |
$20.4m | Series C | ||
$26.0m | Series C | ||
$21.0m | Series D | ||
* | N/A Valuation: €120m 25.9x EV/LTM Revenues | Merger | |
| N/A | N/A Valuation: $166m 32.3x EV/LTM Revenues | IPO | |
| N/A | $8.7m | Post IPO Equity | |
€20.3m Valuation: €32.0m | Acquisition | ||
| Total Funding | CAD102m | ||
